Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
21/04/2026 11:51
April 21 (Reuters) - Merck MRK.N and Eisai's 4523.T experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China